NIH Funding Opportunities

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Funding Opportunity PAR-22-105 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

Funding Opportunity PAR-22-109 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)

Funding Opportunity PAR-22-160 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary statistical analyses of existing dental, oral or craniofacial database resources, or that develop needed statistical methodology for analyzing existing dental, oral or craniofacial databases.

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Funding Opportunity PAR-22-167 from the NIH Guide for Grants and Contracts. The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs) and/or external stakeholders.

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

Funding Opportunity PAR-22-106 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)

Funding Opportunity PAR-22-182 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)

Funding Opportunity PAR-22-183 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain. Research of interest includes but is not limited to Stage I research.

Short-term Mentored Career Enhancement Award in Dental, Oral, and Craniofacial Research for Mid-Career and Senior Investigators (K18- Independent Clinical Trial Not Allowed)

Funding Opportunity PAR-22-121 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Short-term Mentored Career Enhancement (K18) awards in dental, oral, and craniofacial (DOC) research is to provide mid-career and senior investigators with short-term (2.5 months up to 12 months project period) career development experiences in the theories, tools, methods, or approaches of another scientific area to enhance their existing research programs and to broaden opportunities for research experiences and collaborations. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators to facilitate the introduction of DOC research into an existing research program.This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

NICHD Maternal-Fetal Medicine Units (MFMU) Network: Clinical Centers (UG1 Clinical Trial Optional)

Funding Opportunity RFA-HD-23-016 from the NIH Guide for Grants and Contracts. The purpose of the Maternal-Fetal Medicine Units (MFMU) Network is to improve obstetric care, pregnancy health, and outcomes for pregnant and lactating people and their babies. This includes finding ways to: reduce maternal mortality, complications, and morbidities related to pregnancy, labor, and post-partum recovery; reduce prematurity, low-birth weight, infant mortality, and morbidities; and expand the evidence base about the safety and efficacy of therapeutic products used during pregnancy and lactation. NICHD expects the MFMU Network to be its primary and first-line infrastructure involved in implementing multi-site obstetric clinical trials.

Páginas